Image001 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 01)
Losartan Potassium Tablet, Film Coated
Product Images NDC 72789-282
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 72789-282). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image002 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 02)
This text likely represents data from a clinical study evaluating two different medications, Atenolol and Losartan potassium. The study tracked the percentage of patients who achieved a primary endpoint over the course of 66 months. An adjusted risk reduction of 13% was observed with Losartan potassium compared to Atenolol. The p-value of this observation is 0.021, indicating statistical significance.*
Image003 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 03)
This appears to be a chart showing the percentage of patients who experienced fatal or non-fatal stroke during a study that spanned over 66 months. The chart indicates that 6% of patients experienced a stroke. Additionally, it shows the percentage of patients who were taking either atenolol or losartan potassium during the study. The numbers beside the drug names may indicate the percentage of patients taking each drug at different points in time during the study.*
Image004 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 04)
The text seems to be a report of a study on the effectiveness of Losartan Potassium and Atenolol in reducing the incidence of Primary Composite Stroke (Fatal/Non-fatal) in patients. The report includes data on the number of events observed for each treatment group and provides a comparison of the hazard ratio between the groups. The data is stratified by age, gender, race, ISH, Diabetes, and History of CVD. The report also includes a comparison of the hazard ratios for each group.*
Image005 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 05)
The text describes the level of risk reduction of a certain treatment or intervention, which is 16.1%. It also includes a statistical value of p=0.022, which may indicate significance or probability. The remaining text appears to be a graph or chart displaying the percentage of patients experiencing an event, but without further context, it is not possible to determine what the event is or how it relates to the other information provided.*
72789282 Label (72789282)
This is a medication called Losartan Potassium USP. It comes in a quantity of 30 tablets, each tablet containing 25mg of the medication. It is for oral ingestion and has a shelf life until December 2023. This medicine should not be taken during pregnancy. The dosage and instructions for use should be prescribed by a physician. It is important to call a doctor for any side effects and it is possible to report side effects to the FDA. The product appears to be from Oklahoma City, OK. No other relevant information could be obtained from the text.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
